BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2245406)

  • 1. Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells.
    Pommerenke EW; Osswald H; Hahn EW; Volm M
    Cancer Lett; 1990 Nov; 55(1):17-23. PubMed ID: 2245406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.
    Efferth T; Klett T; Mattern J; Osswald H; Pommerenke EW; Stöhr M; Volm M
    Anticancer Res; 1991; 11(3):1275-9. PubMed ID: 1888160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.
    Huet S; Chapey C; Robert J
    Eur J Cancer; 1993; 29A(10):1377-83. PubMed ID: 8398262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of mitomycin C-induced multidrug resistance in vitro.
    Dorr RT; Liddil JD
    Cancer Chemother Pharmacol; 1991; 27(4):290-4. PubMed ID: 1671830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.
    Sehested M; Jensen PB; Skovsgaard T; Bindslev N; Demant EJ; Friche E; Vindeløv L
    Br J Cancer; 1989 Dec; 60(6):809-14. PubMed ID: 2605092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.
    Pommerenke E; Mattern J; Volm M
    J Cancer Res Clin Oncol; 1994; 120(7):422-6. PubMed ID: 8188736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
    Belhoussine R; Morjani H; Manfait M
    Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
    Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
    Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines.
    Kim JH; Chung JB; Park IS; Kim BS; Yoo NC; Choi JH; Roh JK; Kim HS; Kwon OH; Lee KS
    Yonsei Med J; 1993 Mar; 34(1):35-44. PubMed ID: 8397460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.
    Solary E; Velay I; Chauffert B; Bidan JM; Caillot D; Dumas M; Guy H
    Cancer; 1991 Oct; 68(8):1714-9. PubMed ID: 1913513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines.
    Park JG; Lee SK; Hong IG; Kim HS; Lim KH; Choe KJ; Kim WH; Kim YI; Tsuruo T; Gottesman MM
    J Natl Cancer Inst; 1994 May; 86(9):700-5. PubMed ID: 7908989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
    Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
    Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line.
    Bennis S; Ichas F; Robert J
    Int J Cancer; 1995 Jul; 62(3):283-90. PubMed ID: 7628869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles.
    Horio M; Lovelace E; Pastan I; Gottesman MM
    Biochim Biophys Acta; 1991 Jan; 1061(1):106-10. PubMed ID: 1671642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
    Ganapathi R; Grabowski D
    Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
    Kamath N; Grabowski D; Ford J; Ganapathi R
    Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversal of multidrug resistance with (R)-verapamil in vitro and in vivo].
    Pommerenke EW; Mattern J; Traugott U; Volm M
    Arzneimittelforschung; 1991 Aug; 41(8):855-8. PubMed ID: 1781810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
    Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R
    Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdr1 gene expression.
    Belhoussine R; Morjani H; Lahlil R; Manfait M
    Int J Cancer; 1997 Nov; 73(4):600-6. PubMed ID: 9389578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.